17 results about "Dose adjustment" patented technology

This invention belongs to the field of acute lymphoblastic leukemia (ALL) technology and discloses an ALL scoring system. The system divides the entire treatment cycle into three major phases: induction remission, consolidation therapy, and maintenance therapy. Each phase is further subdivided into sub-phases, forming a two-tiered data acquisition architecture. During data collection, baseline data such as age and fusion genes are included, along with dynamic data such as the rate of MRD decline and drug exposure concentration. Simultaneously, anchor triggering mechanisms are set at different sub-phases, making the risk score more closely aligned with the patient's real-time condition and providing a more accurate reference for clinical treatment strategy selection. The feature adaptation module matches subtype-specific biomarkers and analyzes the interaction between rare subtypes and comorbidities. The matching module calls upon a three-dimensional protocol library to select standardized protocols for common subtypes, targeted protocols for rare subtypes, and dose adjustment or drug substitution protocols for patients with comorbidities, matching more suitable protocols for different patients.

Most therapeutic treatments require dose adjustment after initial administration. Dosage adjustment is crucial to ensuring optimal safety and efficacy characteristics of the treatment. Gene therapy is inherently limited by the inability to adjust the dose after initial administration. This invention describes a genetic element capable of dose adjustment after the initial administration of gene therapy. The realization of dose adjustment allows for the replacement of multiple subcutaneous protein injection regimens with single-injection gene therapy, thereby improving pharmacokinetics, safety / efficacy characteristics, medication adherence, and reducing healthcare costs.

This invention relates to the field of clinical medical and nursing device technology, specifically to an auxiliary turntable for blood glucose management and insulin dose adjustment in critically ill patients. It includes a base and a recommendation component. A support column is fixedly connected to the top of the base. The recommendation component includes a recommendation disc fitted outside the support column. A judgment component, including a judgment disc fitted outside the support column, is fitted outside the support column and is located on top of the recommendation cover. An identification component, including an identification disc fitted outside the support column, is fitted outside the support column. A base component, including a base disc fitted outside the support column, is located on top of the identification cover. Through the base, support column, and four sets of adjustment components, standardized and visual matching of multiple blood glucose indicators and insulin adjustment recommendations is achieved. Combined with three-color risk label strips, it quickly identifies abnormal blood glucose levels and fluctuation risks, enabling early detection and intervention, and reducing dose adjustment errors due to experience.

The application is suitable for the field of artificial intelligence and medical health technology, and provides a medicine mutual exclusion identification and dose adjustment method and device and a storage medium, which comprises the following steps: obtaining a first prescription and a second prescription corresponding to a target disease; wherein the first prescription and the second prescription are obtained based on different medical systems; the first prescription comprises at least one first medicine and a first dose corresponding to the first medicine; the second prescription comprises at least one second medicine and a second dose corresponding to the second medicine; identifying medicine mutual exclusion according to the first prescription and the second prescription to obtain a first identification result; and adjusting the first dose according to the first identification result to obtain an adjusted first prescription. The above method provides a safer and more suitable medication scheme for cross-medical system joint diagnosis and treatment.

The present invention relates to an injection mechanism and syringe with an injection dose adjustment function. The injection mechanism (1) has a housing (10) which contains a plunger (80) and an injection dose adjustment means (1a) and a retraction control means (1b) connected to the plunger (80). The injection dose adjustment means (1a) drives the plunger (80) by rotating a tubular member (20) with a dose adjustment knob (30) to drive a drive ring (50), thereby generating elastic potential energy in an elastic means (40).

The application relates to the field of medical data, and discloses a real-time monitoring method for drug efficacy of Chinese and Mongolian and Western medicine based on a biosensing technology, which is used for realizing real-time monitoring of drug efficacy and individualized drug use guidance. The method comprises the following steps: obtaining original sensing signals from real-time multi-modal biosignals collected from the body surface or minimally invasive body fluid samples of a drug user, and obtaining sensor array outputs; extracting real-time pharmacokinetic characteristic signals based on a preset pharmacokinetic model, and mapping the real-time pharmacokinetic characteristic signals into efficacy evaluation parameters according to the types of the drugs; comparing the efficacy evaluation parameters with a preset safe and effective concentration range, and generating real-time drug use state indications and dose adjustment prompt information. The application designs a quantitative evaluation mode for different types of drugs, can compare and generate efficacy state codes and dose adjustment suggestions in real time, comprehensively generates a drug use guidance report, and transmits the drug use guidance report to a drug user end or a clinical monitoring end in real time, so that instant adjustment of a drug use scheme is realized, and the safety and effectiveness of drug use are ensured.

This invention discloses a variable-dose spray assembly and spray device, including a nozzle, a spray pump, and a dose adjustment component. One end of the nozzle has a connecting portion, and the connecting portion has a guide portion. The spray pump is coaxially arranged with the nozzle and compresses its internal space as the nozzle is axially pressed to pump the medication into the nozzle. The dose adjustment component is sleeved with the connecting portion and has a first dose guiding channel and a second dose guiding channel extending along the axial direction of the spray pump. The guide portion can be switched to connect with and move along either the first or second dose guiding channel. The travel distance of the guide portion along the first dose guiding channel is greater than that along the second dose guiding channel. By switching the guide portion with different dose guiding channels, the compressible internal space of the spray pump varies, thereby enabling flexible switching between two doses in a single device, meeting differentiated dosage requirements, and improving the accuracy and convenience of medication administration.

The application discloses a brain tumor disease treatment effect evaluation method, and belongs to the technical field of radiotherapy plan evaluation, and specifically comprises the following steps: acquiring patient brain multi-modal image data and extracting three-dimensional tumor regions and corresponding perfusion parameters; constructing a biological target region hierarchical structure containing tumor overall regions and hypoxic subregions; obtaining a relative hypoxia degree parameter by calculating the cerebral blood flow ratio of the hypoxic subregion to other regions of the tumor; deconstructing historical treatment case data to establish a dose-therapeutic effect correlation parameter set; training a dose adjustment strategy model for the hypoxic subregion; and generating a final radiotherapy dose plan scheme according to the dose adjustment value output by the model combined with a clinical guideline basic dose. The application overcomes the limitations of traditional uniform dose irradiation through a data-driven dose decision mechanism, thereby providing an objective and reliable evaluation basis for clinical selection and optimization of personalized treatment schemes.

Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT Abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%. This data, for application number 2023202402, is current as of 2024-12-02 22:50 AEDT 20 24 27 06 32 03 D ec 2 02 4 0 3 D e c 2 0 2 4 2 0 2 4 2 7 0 6 3 2

The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.

This application discloses an insulin pump dose adjustment method, system, device, and storage medium. The insulin pump dose adjustment method includes acquiring the target user's electronic health record, real-time blood glucose data, and perioperative stress index data, wherein the perioperative stress index data includes the target user's surgical type and anesthesia method; inputting the electronic health record, real-time blood glucose data, and perioperative stress index data into a trained insulin pump dose prediction model to obtain the insulin dose prediction result output by the trained insulin dose prediction model; and converting the insulin dose prediction result according to a preset standardized format to obtain a standardized insulin dose prediction result, which meets the blood glucose management needs of the user during the perioperative period.

The utility model provides a dose adjustment and sound feedback structure when injection pen is adjusted, including casing, adjusting mechanism, dose indication subassembly and feedback subassembly, the near body end of casing is equipped with injection drive mechanism, the far body end of casing is equipped with fixed component, dose indication subassembly is connected with fixed component through meshing structure, meshing structure produces perceptible tactile and auditory feedback in the adjusting process, when the positive rotation of adjusting knob, the angle of the surface of the tooth of dose indication subassembly and fixed component is alpha, alpha angle setting is 10 45 DEG, meshing structure provides smooth guiding angle to reduce resistance, when the reverse rotation of adjusting knob, when the tooth cooperation of the end surface of dose indication subassembly and fixed component, the angle of the surface of the tooth of dose indication subassembly and fixed component is theta, theta angle setting is 60 90 DEG, can prevent dose indication subassembly backoff after dose setting is completed, realizes self -locking.

The utility model discloses an injection device dose two -way adjusting assembly, the utility model provides an injection device dose two -way adjusting assembly, including main shaft, the main shaft rotation is established in the pen body, is provided with the clutch on the main shaft, when the forward dose adjustment, the cantilever of clutch is stuck on the ratchet wheel of pen body, and the main shaft reverse rotation is limited, when the reverse dose adjustment, the cantilever is extruded to the clutch, makes the cantilever and ratchet wheel and removes the restriction to the main shaft reverse rotation and are released. The utility model discloses injection device dose two -way adjusting assembly, sets up the clutch on the main shaft, and the cantilever of clutch and ratchet wheel joint, and the main shaft reverse rotation is limited when forward dose adjustment, when dose adjustment exceeds the dose of expected injection, and reverse rotation dose knob, and the cantilever is extruded to the clutch and makes it and ratchet wheel and removes the restriction to the main shaft reverse rotation and are released and realize reverse dose adjustment, improve the experience feeling of patient use, also can reduce the waste caused by dose and not back call.

This invention proposes a limiting device for setting the maximum single-dose dosage of an injection pen, comprising a housing, with a proximal end at the front end and a distal end at the rear end. A dose display element is spirally connected to the housing. During injection, the dose display element moves towards the distal end along the thread of the housing. During dose adjustment, the dose display element moves towards the proximal end along the thread of the housing. A limiting protrusion is provided on the inner wall of the housing, and a notch is provided on the upper surface of the dose display element. The notch is inclined. When adjusted to the maximum dose, the side of the notch abuts against the side of the limiting protrusion, limiting the continued rotation of the dose display element, thereby limiting the maximum single-dose dosage and preventing the set dose from exceeding the maximum single-dose dosage, resulting in inaccurate single-injection administration.

This invention relates to the field of phototherapy technology, and more particularly to a method and system for intelligent adjustment and monitoring of phototherapy dose. An initial dose plan is generated based on the initial physiological state information of the skin area to be treated. The area is divided into multiple spatial sub-regions, and baseline tolerance thresholds and conduction coefficients are recorded. The response intensity of each sub-region is monitored in parallel. The cross-influence between adjacent sub-regions is calculated using a diffusion-response coupling equation. A cumulative matrix of cross-influence is constructed and superimposed on the baseline tolerance threshold to obtain the predicted tolerance threshold and remaining tolerance margin. While maintaining a constant overall cumulative energy density, the differentiated light intensity adjustment amount is calculated based on the remaining tolerance margin and then executed. This achieves intelligent and personalized phototherapy dose adjustment, improving treatment safety and effectiveness.